Tuesday, March 27, 2012
Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., reported results from the 52 to 56-month follow-up study of patients who participated in the U.S. NX02-0016 study of NX-1207 in benign prostatic hyperplasia (BPH), completed in 2007. Results showed no significant drug safety problems and found that, of patients who received NX-1207 2.5 mg, 52 percent currently were not taking BPH medication and had not received surgical treatments for their BPH, while 36 percent had required no medical or surgical treatments for their BPH since receiving their initial doses of NX-1207 2.5 mg.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.